Efficacy of Oral Medications or Intrauterine Device-Delivered Progestin in Patients with Endometrial Hyperplasia with or without Atypia: A Network Meta-Analysis
review
OA: gold
CC0
⤵ 1 in-corpus citation
Abstract
The aim of this systematic review was to evaluate the efficacy of oral medication or intrauterine device-delivered progestins in patients with endometrial hyperplasia (EH) with or without atypia. We systematically examined PubMed, EMBASE, the Cochrane Library, and clinicaltrials.gov to identify studies reporting the regression rate of patients with EH who received progestins or non-progestins. The regression rates after different treatments were compared using a network meta-analysis in terms of the relative ratios (RRs) and 95% confidence intervals (CIs). Begg-Mazumdar rank correlation and funnel plots were performed to evaluate the publication bias. Five non-randomized studies and 21 randomized controlled trials involving 2268 patients were included in the network meta-analysis. The levonorgestrel-releasing intrauterine system (LNG-IUS) was associated with a higher regression rate than medroxyprogesterone acetate (MPA) (RR 1.30, 95% CI 1.16-1.46) in patients with EH. Among those without atypia, the LNG-IUS was associated with a higher regression rate than any of the three types of oral medications (MPA, norethisterone, or dydrogesterone (DGT)) (RR 1.35, 95% CI 1.18-1.55). According to the network meta-analysis, combining the LNG-IUS with MPA or metformin increased regression rate, while DGT was associated with the highest regression rate among all oral medications. The LNG-IUS may be the best choice for patients with EH, and combining it with MPA or metformin may further improve its efficacy. DGT may be the preferred choice for patients who are unwilling to use the LNG-IUS or who cannot tolerate its side effects.
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (64)
- Comparing the Administration of Letrozole and Megestrol Acetate in the Treatment of Women with Simple Endometrial Hyperplasia without Atypia: A Randomized Clinical Trial via openalex
- Depo-Provera Versus Norethisterone Acetate in Management of Endometrial Hyperplasia Without Atypia via openalex
- Effect of Letrozole on Endometrial Histology in Patients with Disordered Proliferative Endometrium and Simple Hyperplasia via openalex
- Levonorgestrel-Releasing Intrauterine Device Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia via openalex
- Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia. via openalex
- Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials via openalex
- LNG-IUS treatment of non-atypical endometrial hyperplasia in perimenopausal women: a randomized controlled trial via openalex
- Premenopausal abnormal uterine bleeding and risk of endometrial cancer via openalex
- The Efficacy of Dienogest in the Treatment of Simple Endometrial Hyperplasia without Atypia via openalex
- W2021021306 via openalex
- W2022987638 via openalex
- W2037004008 via openalex
- W2046383890 via openalex
- W2063680792 via openalex
- W2094555993 via openalex
- W2095881173 via openalex
- W2101959253 via openalex
- W2107328434 via openalex
- W2125435699 via openalex
- W2125950103 via openalex
- W2138055093 via openalex
- W2185449028 via openalex
- W2283850675 via openalex
- W2327800659 via openalex
- W2531269403 via openalex
- W2554025260 via openalex
- W2557596738 via openalex
- W2598396336 via openalex
- W2612533760 via openalex
- W2613693573 via openalex
- W2801706149 via openalex
- W2911197585 via openalex
- W2958460760 via openalex
- W2970684805 via openalex
- W2978908167 via openalex
- W2990307196 via openalex
- W3002401049 via openalex
- W3042083115 via openalex
- W3047233379 via openalex
- W3125986655 via openalex
- W3150747552 via openalex
- W3177056262 via openalex
- W3197704387 via openalex
- W3197896935 via openalex
- W3210207588 via openalex
- W4205558853 via openalex
- W4212970096 via openalex
- W4289839807 via openalex
- W4296095921 via openalex
- W6640427068 via openalex
- W6678166589 via openalex
- W6678970468 via openalex
- W6695510486 via openalex
- W6737493982 via openalex
- W1924743946 via openalex
- W6797832441 via openalex
- W1929844909 via openalex
- W1964435302 via openalex
- W1966716045 via openalex
- W1975611813 via openalex
- W1981344902 via openalex
- W1989426617 via openalex
- W1990590247 via openalex
- W2012180661 via openalex
Cited by (1)
Source provenance
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0
· commercial use OK